HOME
>
臨床医学：内科
>
皮膚科
> 皮膚科臨床アセット　3　ウイルス性皮膚疾患ハンドブック

皮膚科臨床アセット　3　ウイルス性皮膚疾患ハンドブック

出版社：	中山書店
著者：	古江増隆(総編集) 浅田秀夫(専門編集)
発行日：	2011-05-20
分野：	臨床医学：内科 > 皮膚科
ISBN：	9784521733401
シリーズ：	皮膚科臨床アセット
電子書籍版：	2011-05-20 （初版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

取寄せ目安：8～14営業日

14,300 円(税込)

購入する

電子書籍

章別単位での購入はできません

ブラウザ、アプリ閲覧

14,300 円(税込)

購入する

商品紹介

本書は臨床に登場するウイルスへの対策を網羅し，特にメジャーウイルスであるヘルペスに重点をおきつつ，ヘルペスワクチンや学校保健安全法に従った対応などホットな話題を盛り込んだ最新の臨床ハンドブックである。

目次

皮膚科臨床アセット　3　ウイルス性皮膚疾患ハンドブック

―目次―

1．総論
2．ヘルペスウイルス
3．急性発疹症とウイルス
4．ヒト乳頭腫ウイルス
5．レトロウイルス
6．その他のウイルス

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.2 掲載の参考文献

1) Black JG. Microbiology : Principles and Explorations. 6th ed. Hoboken : John Wiley & Sons ; 2005. 林英生, 岩本愛吉・神谷茂, ほか監訳. ブラック微生物学. 第2版. 東京 : 丸善 ; 2007.

2) White DO, Fenner FL. Medical Virology. 4th ed. New York : Academic Press ; 1994. 北村敬訳. 医学ウイルス学. 第4版. 東京 : 近代出版 ; 1996.

3) 山西弘一監修, 平松啓一, 中込治編. 標準微生物学. 第9版. 東京 : 医学書院 ; 2007.

P.8 掲載の参考文献

1) Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004 ; 5 : 975-9.

2) Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C : efficacy, side effects, and complications. Gut 2006 ; 55 : 1350-9.

3) Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004 ; 5 : 730-7.

4) Honda K, Sakaguchi S, Nakajima C, et al. Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci U S A 2003 ; 100 : 10872-7.

5) Lee HK, Zamora M, Linehan MM, et al. Differential roles of migratory and resident DCs in T cell priming after mucosal or skin HSV-1 infection. J Exp Med 2009 ; 206 : 359-70.

6) Bedoui S, Whitney PG, Waithman J, et al. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol 2009 ; 10 : 488-95.

7) Agace WW. Tissue-tropic effector T cells : generation and targeting opportunities. Nat Rev Immunol 2006 ; 6 : 682-92.

8) Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses : the two extremes of a wide spectrum. Nat Rev Immunol 2006 ; 6 : 231-43.

9) Sawabe T, Uenotsuchi T, Imafuku S, et al. Remission of hepatitis B virus-related vasculitis with lamivudine. Ann Intern Med 2004 ; 140 : 672-3.

10) Orange JS, Ballas ZK. Natural killer cells in human health and disease. Clin Immunol 2006 ; 118 : 1-10.

P.14 掲載の参考文献

1) Knipe DM, et al, editors. Field's Virology. 5th ed. Philadelphia : Lippincott Williams & Wilkins ; 2006.

P.19 掲載の参考文献

1) 岡藤輝夫. 麻疹, ワクチンと二次性ワクチン効果不全による修飾麻疹. 皮膚アレルギーフロンティア 2009 ; 7 : 7-12.

1) 本田まりこ, 新村眞人. ウイルスの検査法. 玉置邦彦, ほか編. 最新皮膚科学大系 1巻. 東京 : 中山書店 ; 2003. pp158-64.

2) 斎田俊明. 皮膚病理組織診断学入門, 改訂第2版. 東京 : 南江堂 ; 2009. pp115, 148, 216-7.

3) 大橋正博, 吉川哲史, 須賀定雄, ほか. 検体検査-ウイルス抗体価. 小児科診療 2003 ; 66 : 251-6.

4) 日野治子. 麻疹. 玉置邦彦, ほか編. 最新皮膚科学大系 15巻. 東京 : 中山書店 ; 2003. pp153-7.

5) 小澤明. 急性発疹症. 瀧川雅浩, ほか編. 標準皮膚科学, 第8版. 東京 : 医学書院 ; 2007. pp547-53.

6) 五十嵐敦之. 伝染性紅斑. 玉置邦彦, ほか編. 最新皮膚科学大系 15巻. 東京 : 中山書店 ; 2003. pp138-42.

P.24 掲載の参考文献

1) AAP. Infection control for hospitalized children. In : AAP Committee on Infectious Diseases ; Pickering LK, editors. Red Book. 28th ed. Elk Grove Village : AAP ; 2009. pp148-61.

2) 庵原俊昭. ワクチンプログラム. 綜合臨牀 2010 ; 59 : 349-53.

3) 庵原俊昭. 麻疹・風疹・水痘・ムンプスに対する病院および地域における感染制御対策の最近の動向. 医療 2006 ; 60 : 483-8.

4) 庵原俊昭. 麻疹・風疹・ムンプス (流行性耳下腺炎) ・水痘感染対策-抗体測定とその評価. CAMPUS HEALTH 2008 ; 45 : 9-14.

5) 庵原俊昭. ウイルス感染症診断に必要な検査とその読み方. 日皮会誌 2008 ; 118 : 2727-30.

6) 庵原俊昭. ムンプス. 臨床とウイルス 2002 ; 30 : 28-32.

7) CDC. Prevention and control of seasonal influenza with vaccines. MMWR 2009 ; 58 (RR-8) : 1-52.

8) European consensus group on hepatitis B immunity. Are booster immunizations needed for lifelong hepatitis B immunity? Lancet 2000 ; 355 : 561-5.

9) CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR 2006 ; 55 (RR-16) : 1-33.

P.29 掲載の参考文献

1) Sutkowski N, Conrad B, Thorley-Lawson DA, et al. Epstein-Barr virus transactivates the human endogenous retrovirus HERV-K18 that encodes a superantigen. Immunity 2001 ; 15 : 579-89.

2) Renn CN, Straff W, Dremuller A, et al. Ammoxicillin-induced exanthema in young adults with infectious mononucleosis : demonstration of drug-specific lymphocyte reactivity. Br J Dermatol 2002 ; 147 : 1166-70.

3) Saito-Katsuragi M, Asada H, Yokoi S, et al. Ampicillin-induced cutaneous eruption associated with Epstein-Barr virus reactivation. J Am Acad Dermatol 2005 ; 52 : S127-8.

4) Coopman SA, Johnson RA, Platt R, et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993 ; 328 : 1670-4.

5) Eggena MP, Barugahare B, Jones N, et al. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol 2005 ; 174 : 4407-14.

6) Smith KJ, Skelton HG, Yeager J, et al. Increased drug reactions in HIV-1 positive patients : a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. The Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). Clin Exp Dermatol 1997 ; 22 : 118-23.

7) 蒲原毅, 高橋一夫, 三谷直子, ほか. ウイルス感染の関与が示唆された塩酸エペリゾン, フルコナゾールによる重症薬疹の1例. 皮膚臨床 2004 ; 46 : 995-8.

8) Dlev J, Reyter I, Mauerer T. Treatment of recurring cutaneous drug reactions in patients with human immunodeficiency virus 1 infection : a series of 3 cases. Arch Dermatol 2004 ; 140 : 1051-3.

9) Reider MJ, Shear NH, Kanee A, et al. Prominence of slow acetylator phenotype among patients with sulphonamide hypersensitivity reactions. Clin Pharmacol Ther 1991 ; 49 : 13-7.

10) Ohshima K. Pathological features of diseases associated with human T-cell leukemia virus type I. Cancer Sci 2007 ; 98 : 772-8.

11) Nishioka K, Maruyama I, Sato K, et al. Chronic inflammatory arthropathy associated with HTLV-I. Lancet 1989 ; 1 : 441.

12) Terada K, katamine S, Rguchi K, et al. Prevalence of serum and salivary antibodies to HTLV-I in Sjogren's syndrome. Lancet 1994 ; 334 : 1116-9.

13) Yamano Y, Takenouchi N, Li HC, et al. Virus-induced dysfunction of CD4+ CD25+ T cells in patients with HTLV-I associated neuroimmunological disease. J Clin Invest 2005 ; 115 : 1361-8.

14) Ch U, Grant C, Griffith C, et al. Reduced Foxp 3 protein expression is associated with inflammatory diseases during human T lymphotropic virus type I infection. J Infect Dis 2006 ; 193 : 1557-66.

15) Datta A, Shinha-Datta U, Dhillon NK, et al. The HTLV-I p30 interferes with TLR4 signaling and modulates the release of pro and anti-inflammatory cytokines from human macrophages. J Biol Chem 2006 ; 281 : 23414-24.

16) Suzuki Y, Inagi R, Aono T, et al. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol 1998 ; 134 : 1108-12.

17) Tohyama M, Yahata Y, Yasukawa M, et al. Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Arch Dermatol 1998 ; 134 : 1113-7.

18) Aihara M, Sugita Y, Takahashi S, et al. Anticonvulsant hypersensitivity syndrome associated with reactivation of cytomegalovirus. Br J Dermatol 2001 ; 144 : 1231-4.

19) Mitani N, Aihara M, Yamakawa Y, et al. Drug-induced hypersensitivity syndrome due to cyanamide associated with multiple reactivation of human herpesviruses. J Med Virol 2005 ; 75 : 430-4.

20) Aihara M, Mitani N, Kakemizu N, et al. Human herpesvirus infection in druginduced hypersensitivity syndrome, toxic epidermal necrolysis and Stevens-Johnson syndrome. Allergology International 2004 ; 53 : 23-9.

21) Teraki Y, Murota H, Izaki S. Toxic Epidermal Necrolysis due to zonisamide associated with reactivation of human herpesvirus 6. Arch Dermatol 2008 ; 114 : 232-5.

II ヘルペスウイルス

P.34 掲載の参考文献

1) McGeoch DJ, Cook S, Dolan A, et al. Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses. J Mol Biol 1995 ; 247 : 443-58.

2) Roizmann B, Desrosiers RC, Fleckenstein B, et al. The family Herpesviridae : An update. The Herpesvirus Study Group of the International Committee on Taxonomy of Viruses. Arch Virol 1992 ; 123 : 425-49.

3) Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964 ; 1 : 702-3.

4) Kondo K, Kaneshima H, Mocarski ES. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci U S A 1994 ; 91 : 11879-83.

5) Salahuddin SZ, Ablashi DV, Markham PD, et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 1986 ; 234 : 596-601.

6) Yamanishi K, Okuno T, Shiraki K, et al. Identification of human herpesvirus 6 as a causal agent for exanthem subitum. Lancet 1988 ; 1 : 1065-7.

7) Kondo K, Kondo T, Okuno T, et al. Latent human herpesvirus 6 infection of human monocytes/macrophages. J Gen Virol 1991 ; 72 : 1401-8.

8) Frenkel N, Schirmer EC, Wyatt LS, et al. Isolation of a new herpesvirus from human CD4+T cells. Proc Natl Acad Sci USA 1990 ; 87 : 748-752.

9) Tanaka K, Kondo T, Torigoe S, et al. Human herpesvirus 7 : Another causal agent for roseola (exanthem subitum). J Pediatr 1994 ; 125 : 1-5.

10) Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994 ; 266 : 1865-9.

P.39 掲載の参考文献

1) 安元慎一郎, 単純性疱疹. 玉置邦彦, ほか編. 最新皮膚科学大系第15巻. ウイルス性疾患性感染症. 東京 : 中山書店 ; 2003. pp8-19.

2) Yoshikawa T, Hill JM, Stanberry LR, et al. The characteristic site-specific reactivation phenotypes of HSV-1 and HSV-2 depend upon the latency-associated transcript region.J Exp Med ; 1996 : 184 : 659-64.

3) Umbach JL, Kramer MF, Jurak I, et al. Micro RNAs expressed by herpes simplex virus 1 during latent infection regulate viral mRNAs. Nature 2008 ; 454 : 780-3.

4) 本田まりこ. 性器ヘルペス. 性感染症診断・治療ガイドライン. 日性感染症誌 2008 ; 19 : s62-6.

5) 早川潤, 早川謙一, 南八重子, ほか. イムノクロマト法を測定原理とする単純ヘルペスウイルス抗原検出キットの臨床的性能評価. 日性感染症誌 2010 ; 21 : 134-8.

P.45 掲載の参考文献

1) 本田まりこ, 新村眞人. 再発性性器ヘルペスにおけるアシクロビル錠長期継続投与後の臨床効果. カレントテラピー 1993 ; 11 : 1569-74.

2) Sawtell NM. The probability of in vivo reactivation of herpes simplex virus type 1 increases with the number of latently infected neurons in the ganglia. J Virol 1998 ; 72 : 6888-92.

3) Honda M, Okuda T, Hasegawa T, et al. Effect of long-term, low-dose acyclovir suppressive therapy on susceptibility to acyclovir and frequency of acyclovir resistance of herpes simplex virus type 2. Antiviral Chemistry & Chemotherapy 2001 ; 12 : 233-9.

4) Hellden A, Odar-Cederlof I, Diener P, et al. High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects : an observational study. Nephrol Dial Transplant 2003 ; 18 : 1135-41.

5) 鳥羽研二. 腎・泌尿器疾患の特徴. 日医雑誌 2009 ; 138 : 236-8.

6) 本田まりこ. 腎機能低下患者における抗ウイルス薬アシクロビルの使い方. 臨床医薬 2004 ; 20 (4) : 1-8.

P.50 掲載の参考文献

1) Goodyear HM, McLeish P, Randall S, et al. Immunological studies of herpes simplex virus infection in children with atopic eczema. Br J Dermatol 1996 ; 134 : 85-93.

2) 本田まりこ, 新村眞人. カポジ水痘様発疹症. 皮膚臨床 1998 ; 40 : 940-1.

3) 中川秀己. カポジ水痘様発疹症とアトピー性皮膚炎. アレルギーの臨床 2000 ; 20 : 538-9.

4) Bork K, Brauninger W. Increasing incidence of eczema herpeticum : analysis of seventy-five cases. J Am Acad Dermatol 1988 ; 19 : 1024-9.

5) 本田まりこ, 新村眞人. カポジ水痘様発疹症-どう対処すべきか. 宮地良樹編. アトピー性皮膚炎治療-最新のトピックス. 東京 : 先端医学社 ; 1996. pp135-42.

6) 庄司純, 稲田紀子, 斎藤圭子, ほか. カポジ水痘様発疹症における前眼部病変の検討. 眼科 1999 ; 41 : 291-6.

P.55 掲載の参考文献

1) Obara Y, Furuta Y, Takasu T, et al. Distribution of herpes simplex virus types 1 and 2 genomes in human spinal ganglia studied by PCR and in situ hybridization. J Med Virol 1997 ; 52 : 136-42.

2) Zhu J, Koelle DM, Cao J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007 ; 204 : 595-603.

3) Brice SL, Krzemien D, Weston WL, et al. Detection of herpes simplex virus DNA in cutaneous lesions of erythema multiforme. J Invest Dermatol 1989 ; 93 : 183-7.

4) Miura S, Smith CC, Burnett JW, et al. Detection of viral DNA within skin of healed recurrent herpes simplex infection and erythema multiforme lesions. J Invest Dermatol 1992 ; 98 : 68-72.

5) Imafuku S, Kokuba H, Aurelian L, et al. Expression of herpes simplex virus DNA fragments located in epidermal keratinocytes and germinative cells is associated with the development of erythema multiforme lesions. J Invest Dermatol 1997 ; 109 : 550-6.

6) 今福信一. さまざまな紅斑症単純ヘルペスと多形紅斑. Derma 2007 ; 122 : 37-43.

P.58 掲載の参考文献

1) Kelly E, Russell SJ. History of oncolytic viruses : genesis to genetic engineering. Molecular Therapy 2007 ; 15 : 651-9.

2) Watanabe D. Medical application of herpes simplex virus. J Dermatol Sci 2010 ; 57 : 75-82.

3) 西山幸廣, 五島典. 単純ヘルペスウイルスを利用した癌に対するウイルス療法. ウイルス 2007 : 57 : 57-66.

P.61 掲載の参考文献

1) Grose C. Variation on a theme by Fenner : the pathogenesis of chickenpox. Pediatrics 1981 ; 68 : 735-7.

2) Ku CC, Zerboni L, Ito H, et al. Varicella-zoster virus transfer to skin by T cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med 2004 ; 200 : 917-25.

3) Patel RA, Binns HJ, Shulman ST. Reduction in pediatric hospitalizations for varicella-related invasive group A streptococcal infections in the varicella vaccine era. J Pediatr 2004 ; 144 : 68-74.

4) Pastuszak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 1994 ; 330 : 901-5.

5) 尾崎隆男. 水痘. 臨床とウイルス 2002 ; 30 : 33-9.

6) Takahashi M, Otsuka T, Okuno Y, et al. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974 ; 2 : 1288-90.

7) Asano Y, Hirose S, Iwayama S, et al. Protective effect of immediate inoculation of a live varicella vaccine in household contacts in relation to the viral dose and interval between exposure and vaccination. Biken J 1982 : 25 : 43-5.

8) Asano Y, Varicella vaccine : The Japanese experience. J Infect Dis 1996 ; 174 (Suppl 3) : S310-3.

9) Ozaki T, Nishimura N, Kajita Y. Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects ; 10-year survey at pediatric clinic. Vaccine 2000 ; 18 ; 2375-80.

10) Ozaki T, Nishimura N, Muto T, et al. Safety and immunogenicity of gelatinfree varicella vaccine in epidemiological and serological studies in Japan. Vaccine 2005 ; 23 : 1205-8.

P.67 掲載の参考文献

1) Toyama N, Shiraki K, Members of the Society of the Miyazaki Prefecture Dermatorogists. Epidemiology of herpes zoster and its relationship to varicella in Japan : A 10-year of 48,388 herpes zoster cases in Miyazaki Prefecture. J Med Virol 2009 ; 81 : 2053-8.

2) Johnson R, Mandal B, Bowsher D, et al. Guidelines for the management of shingles. Report of a working group of the British Society for the study infection. J Infect 1995 ; 30 : 193-200.

3) Peyramond D, Chidiac C, Lucht F, et al. Management of infections due to the varicella-zoster virus. Eur J Dermatol 1998 ; 8 : 397-402.

4) Gross G, Schofer H, Wassilew S, et al. Herpes zoster guideline of the German Dermatology Society. J Clin Virol 2003 ; 26 : 277-89.

5) Lungu O, Annunziato PW, Gershon A, et al. Reactivated and latent varicellazoster virus in human dorsal root ganglia. Proc Natl Acad Sci U S A 1995 ; 92 : 10980-4.

6) 漆畑修. 帯状疱疹. 玉置邦彦, ほか編. 最新皮膚科学大系 15巻. ウイルス性疾患性感染症. 東京 : 中山書店 ; 2003. pp33-41.

7) Muraki R, Iwasaki T, Sata T, et al. Immunohistochemical study of skin lesions in herpes zoster. Virchows Arch A Pathol Anat Histopathol 1992 ; 420 : 71-6.

8) 漆畑修. 帯状疱疹. 泉孝英編. ガイドライン外来診療 2006. 東京 : 日経メディカル開発 ; 2006. pp250-5.

9) 漆畑修. Ramsay Hunt syndrome. 玉置邦彦, ほか編. 最新皮膚科学大系特別巻2. 皮膚科症候群. 東京 : 中山書店 ; 2004. pp292-3.

10) 漆畑修. 帯状疱疹の病態と治療の基本. 臨床と薬物治療 2001 ; 20 : 1020-5.

11) 漆畑修. 帯状疱疹治療における抗ヘルペスウイルス薬の位置づけ. 日経ドラッグインフォメーション 2008 ; 11月号 : 33-5.

12) 漆畑修. 帯状疱疹のステロイド内服療法. 臨床皮膚科 1995 ; 49 (増刊5) : 164-5.

13) Vossen MT, Grnt MR, Weel JF, et al. Development of virus-specific CD4+ T cells on reexposure to Varicella-Zoster virus. J Infect Dis 2004 ; 190 : 72-82.

14) Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005 ; 352 : 2271-84.

P.77 掲載の参考文献

1) 川井康嗣, 白源清貴, 又吉宏昭, ほか. 帯状疱疹後神経痛の特徴と治療. ペインクリニック 2008 ; 29 : S137-49.

2) 小澤明. 痛みのある皮膚疾患-帯状疱疹を中心に. 診断と治療 2007 ; 95 : 1537-44.

3) Dubinsky RM, Kabbani H, El-Chami Z, et al. Practice parameter : treatment of postherpetic neuralgia : an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004 ; 63 : 959-65.

4) 比嘉和夫, 廣田一紀, 仁田原慶一. 帯状疱疹後神経痛-診断と治療. ペインクリニック 2009 ; 30 : S413-20.

5) Ozawa A, Miyahara M, Sugai J, et al. HLA class I and II alleles and susceptibility to generalized pustular psoriasis : significant associations with HLA-Cw1 and HLA-DQB1*303. Dermatol 1998 ; 25 : 573-81.

6) 小澤明. 帯状疱疹後神経痛に対するイオントフォレーシス療法. 日本医事新報 1997 ; 3841 : 27-30.

7) Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005 ; 352 : 2271-84.

P.84 掲載の参考文献

1) Satyaprakash AK, Tremaine AM, Stelter AA, et al. Viremia in acute herpes zoster. J Infect Dis 2009 ; 200 : 26-32.

2) Sampathkumar P, Drage LA, Martin DP. Herpes Zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc 2009 ; 84 : 274-80.

P.88 掲載の参考文献

1) Asano Y, Nakayama H, Yazaki T, et al. Protection against varicella in family contacts by immediate inoculation with live varicella vaccine. Pediatrics 1977 ; 59 : 3-7.

2) 須賀定雄, 浅野喜造. 曝露後発症予防 (Post-exposure Prophylaxis : PEP) 水痘 (ワクチン). 臨床と微生 2008 ; 35 : 657-61.

3) Gomi Y, Sunamachi H, Mori Y, et al. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol 2002 ; 76 : 11447-59.

4) Asano Y, Suga S, Yoshikawa T, et al. Experience and reason : twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 1994 ; 94 : 524-6.

5) 須賀定雄, 浅野喜造. 終生免疫の神話-Breakthrough varicella, 水痘ワクチンの生涯スケジュール. 臨床とウイルス 2008 ; 36 : 55-60.

6) Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster : recommendations of the advisory committee on immunization practices (ACIP). MMWR 2008 ; 57 : 1-30.

7) Takahashi M, Okada S, Miyagawa H, et al. Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay. Vaccine 2003 ; 21 : 3845-53.

8) Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005 ; 352 : 2271-84.

9) Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008 ; 197 : 825-35.

P.94 掲載の参考文献

1) Yamanishi K, Okuno T, Shiraki K, et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1988 ; 1 : 1065-7.

2) Yoshikawa T, Ihira M, Suzuki K, et al. Primary human herpesvirus 6 infection in liver transplant recipients. J Pediatr 2001 ; 138 : 921-5.

3) Yoshikawa T, Kobayashi I, Asano Y, et al. Clinical features of primary human herpesvirus-6 infection in an infant with acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1993 ; 15 : 424-6.

4) Asano Y, Yoshikawa T, Suga S, et al. Viremia and neutralizing antibody response in infants with exanthem subitum. J Pediatr 1989 ; 114 : 535-9.

5) Salahuddin SZ, Ablashi DV, Markham PD, et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 1986 ; 234 : 596-601.

6) Frenkel N, Schirmer EC, Wyatt LS, et al. Isolation of a new herpesvirus from human CD4+ T cells. Proc Natl Acad Sci U S A 1990 ; 87 : 748-52.

7) Tanaka K, Kondo T, Torigoe S, et al. Human herpesvirus 7 : another causal agent for roseola (exanthem subitum). J Pediatr 1994 ; 125 : 1-5.

8) Kumagai T, Yoshikawa T, Yoshida M, et al. Time course characteristics of human herpesvirus 6 specific cellular immune response and natural killer cell activity in patients with exanthema subitum. J Med Virol 2006 ; 78 : 792-9.

9) Kondo K, Nagafuji H, Hata A, et al. Association of human herpesvirus 6 infection of the central nervous system with recurrence of febrile convulsions. J Infect Dis 1993 ; 167 : 1197-200.

10) Asano Y, Yoshikawa T, Suga S, et al. Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum). Pediatrics 1994 ; 93 : 104-8.

11) Suga S, Yoshikawa T, Asano Y, et al. Human herpesvirus-6 infection (exanthem subitum) without rash. Pediatrics 1989 ; 83 : 1003-6.

12) Yoshikawa T, Suzuki K, Umemura K, et al. Atypical clinical features of a human herpesvirus-6 infection in a neonate. J Med Virol 2004 ; 74 : 463-6.

13) Asano Y, Suga S, Yoshikawa T, et al. Human herpesvirus type 6 infection (exanthem subitum) without fever. J Pediatr 1989 ; 115 : 264-5.

14) Hall CB, Long CE, Schnabel KC, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med 1994 ; 331 : 432-8.

15) Yoshikawa T, Goshima F, Akimoto S, et al. Human herpesvirus 6 infection of human epidermal cell line : pathogenesis of skin manifestations. J Med Virol 2003 ; 71 : 62-8.

P.99 掲載の参考文献

1) 田中淳之. βヘルペスウイルスの感染と増殖機構. 日本臨牀 2006 (増刊) ; 64 : 400-3.

2) Kitamura K, Asada H, Iida H, et al. Relationship among human herpesvirus 6 reactivation, serum interleukin 10 levels and rash/graft-versus-host disease after allogeneic stem cell transplantation. J Am Acad Dermatol 2008 ; 58 : 802-9.

3) Shiohara T, Inaoka M, Yoko K. Drug-induced hypersensitivity syndrome (DIHS) : a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 2006 ; 55 : 1-8.

4) Watanabe H, Tohyama M, Kamijima M, et al. Occupational trichloroethylene hypersensitivity syndrome with human herpesvirus-6 and cytomegalovirus reactivation. Dermatology 2009 ; 30 : 1-6.

5) Sakuma K, Kano Y, Fukuhara M, et al. Syndrome of inappropriate secretion of antidiuretic hormone associated with limbic encephalitis in a patient with druginduced hypersensitivity syndrome. Clin Exp Dermatol 2008 ; 33 : 287-90.

6) Takahashi R, Kano Y, Yamazaki Y, et al. Defective regulatory T cells in patients with severe drug eruptions : timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 2009 ; 182 : 8071-9.

7) Kano Y, Hirahara K, Sakuma K, et al. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graftversus-host disease. Br J Dermatol 2006 ; 155 : 301-6.

8) 三浦正義, 原田浩, 小川弥生, ほか. 腎移植後BKウイルス腎症と拒絶反応. 腎移植・血管外科 2007 ; 19 : 173-8.

9) Aota N, Shiohara T. Viral connection between drug rashes and autoimmune diseases : how autoimmune responses are generated after resolution of drug rashes. Autoimmun Rev 2009 ; 8 : 488-94.

10) Camille R, Massih A, Razonable RR. Human herpesvirus 6 infections after liver transplantation. World J Gastroenterol 2009 ; 15 : 2561-9.

11) Tomonari A, Takahashi S, Ooi J, et al. Human herpesvirus variant A infection with fever, skin rash, and liver dysfunction in a patient after unrelated cord blood transplantation. Bone Marrow Transplant 2005 ; 36 : 1109-10.

12) Suzuki H, Asai T, Tamaki Z, et al. Drug-induced hypersensitivity syndrome with rapid hematopoietic reconstitution during treatment for acute myeloid leukemia. Haematologica 2008 ; 93 : 469-70.

P.104 掲載の参考文献

1) Kondo K, Nagafuji H, Hata A, et al. Association of human herpesvirus 6 infection of the central nervous system with recurrence of febrile convulsions. J Infect Dis 1993 ; 167 : 1197-200.

2) Kondo K, Kondo T, Okuno T, et al. Latent human herpesvirus 6 infection of human monocytes/macrophages. J Gen Virol 1991 ; 72 : 1401-8.

3) Tanaka-Taya K, Sashihara J, Kurahashi H, et al. Human herpesvirus 6 (HHV-6) transmits from parent to child by integration form and characterization of cases with chromosomally integrated HHV-6 DNA. J Med Virol 2004 ; 73 (3) : 465-73.

4) Arbuckle JH, Medveczky MM, Luka J, et al. The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes in vivo and in vitro. Proc Natl Acad Sci U S A 2010 ; 107 (12) : 5563-8.

5) Kondo K, Shimada K, Sashihara J, et al. Identification of human herpesvirus 6 latency-associated transcripts. J Virol 2002 ; 76 : 4145-51.

6) Kondo K, Sashihara J, Shimada K, et al. Recognition of a Novel Stage of Beta-Herpesvirus Latency in Human Herpesvirus 6. J Virol 2003 ; 77 (3) : 2258-64.

7) Ablashi DV, Eastman HB, Owen CB, et al. Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients. J Clin Virol 2000 ; 16 : 179-91.

P.108 掲載の参考文献

1) 本田まり子. ヘルペスウイルス感染症. 日皮会誌 2007 ; 117 : 767-76.

2) 山本剛伸, 岩月啓氏. HHV-6・HHV-7・HHV-8. 皮膚臨床 2006 ; 48 : 1337-41.

3) Frenkel N, Shicrmer EC, Syatt LS, et al. Isolation of a new herpesvirus from human CD4+ T cells. Proc Natl Acad Sci USA 1990 ; 87 : 748-52.

4) 須賀定雄. 突発性発疹症. 日本臨牀 2006 ; 64 (増刊) : 472-5.

5) Salahuddin SZ, Ablashi DV, Markham PD, et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science 1986 ; 234 : 596-601.

6) Yamanishi K, Okuno T, Shiraki K, et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1988 ; 1 ; 1065-7.

7) Tanaka K, Kondo T, torigoe S, et al. Human herpesvirus 7 : another causal agent for roseola (exanthem subitum). J pediatr 1994 ; 125 : 1-5.

8) Hidaka Y, Okada K, Kusuhara K, et al. Exanthem subitum and human herpesvirus 7 infection. Pediatr Infect Dis J 1994 ; 13 : 1010-1.

9) 藤山幹子, 橋本公二. 薬剤性過敏症症候群とHHV-6の再活性化について. ウイルス 2009 ; 59 : 23-30.

10) Shiohara T, Kano Y. A complex interaction between drug allergy and viral infection. Clin Rev Allergy Immunol 2007 ; 33 : 124-33.

11) Yamagami A, Yoshikawa T, Asano Y, et al. Drug-induced hypersensitivity syndrome due to mexiletine hydrochloride associated with reactivation of human herpesvirus 7. Dermatology 2006 ; 213 : 341-4.

12) 藤山幹子, 橋本公二. Drug-induced hypersensitivity syndrome (DIHS) におけるウイルス検査. 臨床皮膚科 2008 ; 62 : 68-71.

13) 渡邉孝宏. ジベル氏ばら色粃糠疹とHHV-7. アレルギー科 2004 ; 18 : 312-7.

14) Percival GH. Pityriasis rosea. Br J Dermatol 1932 ; 44 : 241-53.

15) Bjornberg A, Hellgren L. Pityriasis rosea. A statistical, clinical, and laboratory investigation of 826 patients and matched healthy controls. Acta Derm Venereol 1962 ; 42 (Suppl 50) : 1-68.

16) Crissey JT. Pityriasis rosea. Pediatr Clin North Am 1956 ; 27 : 801-9.

17) Parsons JM. Pityriasis rosea update : 1986. J Am Acad Dermatol 1986 ; 15 : 159-67.

18) Drago F, Ranieri E, Malaguti F, et al. Human herpesvirus 7 in pityriasis rosea. Lancet 1997 ; 349 ; 1367-8.

19) Drago F, Ranieri E, Malaguti F, et al. Human herpesvirus 7 in patients with pityriasis rosea. Electron microscopy investigations and polymerase chain reactions in mononuclear cells, plasma and skin. Dermatology 1997 ; 195 ; 374-8.

20) Drago F, Malaguti F, Ranieri E, et al. Human herpes virus-like particles in pityriasis rosea lesions : an electron microscopy stydy. J Cutan Pathol 2002 ; 29 : 359-61.

21) Watanabe T, Kawamura T, Jacob SE, et al. Pityriasis rosea is associated with systemic active infection with both human herpesvirus (HHV)-7 and human herpesvirus 6 in blood. J Invest Dermatol 2002 ; 119 : 793-7.

22) Drago F, Broccolo F, Rebora A, et al. Pityriasis rosea : an update with a critical appraisal of its possible herpesviral etiology. J Am Acad Dermatol 2009 ; 61 : 303-18.

P.116 掲載の参考文献

1) 干場勉, 朝本明弘, 矢吹朗彦. βヘルペスウイルスの抗体保有率. 日本臨牀 2006 ; 64 (増刊) : 451-4.

2) 岩本和真, 三原祥嗣, 大原直樹, ほか. 全身性エリテマトーデスに生じたサイトメガロウイルス肺炎. 皮膚臨床 2008 ; 50 : 77-80.

3) 何川宇啓, 浅野祐介, 福田知雄, ほか. サイトメガロウイルスによる消化管出血をきたした薬剤性過敏症症候群の1例. 臨皮 2008 ; 62 : 278-81.

4) 相楽玲, 山本真里, 永田茂樹, ほか. Immune cytopeniaに伴う外陰部皮膚潰瘍がサイトメガロウイルス感染により難治化した1例. 臨皮 2008 ; 62 : 159-62.

5) 岩崎琢也. βヘルペスウイルスの病原性発現機構. 日本臨牀 2006 ; 64 (増刊) : 427-34.

6) 吉田正己. サイトメガロウイルス感染症. 玉置邦彦, ほか編. 最新皮膚科学大系 15巻, ウイルス性疾患性感染症. 東京 : 中山書店 ; 2003. pp47-51.

7) 橋本公二. Drug-induced hypersensitivity syndrome (DIHS). 日皮会誌 2006 ; 116 : 1575-81.

8) Tanaka Y, Kanda Y, Kami M, et al. Monitoring cytomegalovirus infection by antigenemia assay and two distinct plasma rea-time PCR methods after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003 ; 30 : 315-9.

P.122 掲載の参考文献

1) Kasahara Y, Yachie A, Takei K, et al. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 2001 ; 98 : 1882-8.

2) Yoshida M, Tsuda N, Morihata T, et al. Five patients with localized facial eruptions associated with Gianotti-Crosti syndrome caused by primary Epstein-Barr virus infection. J Pediatr 2004 ; 145 : 843-4.

3) Wakiguchi H, Hisakawa H, Kubota H, et al. Strong response of T cells in infants with dual infection by Epstein-Barr virus and cytomegalovirus. Pediatr Int 1999 ; 41 : 484-9.

4) 脇口宏, 前田明彦, 堂野純孝, ほか. IV. γヘルペスウイルス-EBウイルス (EBV) とカポジ肉腫関連ヘルペスウイルス (KSHV). 6. γヘルペスウイルス感染症. 1) 伝染性単核症. 日本臨牀 2006 ; 64 (3) : 625-9.

5) Dohno S, Maeda A, Ishiura Y, et al. Diagnosis of infectious mononucleosis caused by Epstein-Barr virus in infants. Pediatr Internat 2010 ; 52 : 536-40.

6) 前田明彦, 佐藤哲也, 石浦嘉人, ほか. 慢性活動性EBウイルス感染症-この10年間で解明されたこと. 臨床とウイルス 2006 ; 34 (3) : 123-32.

7) 前田明彦, 藤枝幹也, 佐藤哲也, ほか. EBウイルス感染症. 小児内科 2007 ; 39 : 1996-2002.

P.127 掲載の参考文献

1) Rickinson AB, Murray RJ, Brooks J, et al. T cell recognition of Epstein-Barr virus associated lymphomas. Cancer Surv 1992 ; 13 : 53-80.

2) Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders : classification and treatment. Oncologist 2008 ; 13 : 577-85.

3) Swerdlow SH, Campo E, Harris NL, et al, editors. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon : IARC Press ; 2008.

4) Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan : incidence of recently recognized entities. Pathol Int 2000 ; 50 : 696-702.

5) Suzuki R, Takeuchi K, Ohshima K, et al. Extranodal NK/T-cell lymphoma : diagnosis and treatment cues. Hematol Oncol 2008 ; 26 : 66-72.

6) Kato S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 2007 ; 18 : 1685-90.

7) Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome : a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007 ; 110 : 479-84.

8) Jaffe ES, Harris NL, Stein H, et al, editors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France : IARC Press ; 2001.

9) Gaulard P, Swerdlow SH, Harris NL. et al. Other iatrogenic immunodeficiencyassociated lymphoproliferative disorders. In : Swerdlow SH, editors. WHO classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon : IARC Press ; 2008. pp350-1.

10) Starkebaum G. Rheumatoid arthritis, methotrexate, and lymphoma : risk substitution, or cat and mouse with Epstein-Barr virus? J Rheumatol 2001 ; 28 : 2573-75.

11) Oyama T, Ichimura K, Suzuki R, et al. Senile EBV+ B-cell lymphoproliferative disorders : a clinicopathologic study of 22 patients. Am J Surg Pathol 2003 ; 27 : 16-26.

12) Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group : a study of 96 patients. Clin Cancer Res 2007 ; 13 : 5124-32.

13) Martin B, Whittaker S, Morris S, et al. A case of primary cutaneous senile EBV-related diffuse large B-cell lymphoma. Am J Dermatopathol 2010 ; 32 : 190-3.

14) Pittaluga S, Wilson WH, Jaffe ES. Lymphomatoid granulomatosis. In : Swerdlow SH, editors. WHO classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon : IARC Press ; 2008. pp247-9.

15) Liebow AA, Carrington CR, Friedman PJ. Lymphomatoid granulomatosis. Human Pathol 1972 ; 3 : 457-558.

16) Beaty MW, Toro J, Sorbara L, et al. Cutaneous lymphomatoid granulomatosis : correlation of clinical and biologic features. Am J Surg Pathol 2001 ; 25 : 1111-20.

P.134 掲載の参考文献

1) Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000 ; 343 : 481-92.

2) Straus SE. The chronic mononucleosis syndrome. J Infect Dis 1988 ; 157 : 405-12.

3) Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001 ; 98 : 280-6.

4) Kimura H, Hoshino Y, Hara S, et al. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection. J Infect Dis 2005 ; 191 : 531-9.

5) Kawa K, Okamura T, Yagi K, et al. Mosquito allergy and Epstein-Barr virusassociated T/natural killer-cell lymphoproliferative disease. Blood 2001 ; 98 : 3173-4.

6) 脇口宏, 前田明彦. ウイルスと血液疾患-血球貪食症候群とウイルス. 日児誌 2002 ; 106 : 1211-16.

7) 木村宏. 慢性活動性Epstein-Barr Virus感染症. 日小血会誌 2006 ; 20 : 572-80.

8) Kimura H, Tsuge I, Imai S, et al. Intact antigen presentation for Epstein-Barr virus (EBV)-specific CTL by a lymphoblastoid cell line established from a patient with severe chronic active EBV infection. Med Microbiol Immunol (Berl) 1995 ; 184 : 63-8.

9) Sugaya N, Kimura H, Hara S, et al. Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T cells in patients with chronic active EBV infection. J Infect Dis 2004 ; 190 : 985-8.

10) Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 2003 ; 187 : 527-33.

11) Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999 ; 37 : 132-6.

12) 木村宏, 河敬世, 大石勉, ほか. 慢性活動性EBウイルス感染症の長期予後について. 日児誌 2006 ; 110 : 1578-80.

13) Gotoh K, Ito Y, Shibata-Watanabe Y, et al. Clinical and virological characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation. Clin Infect Dis 2008 ; 46 : 1525-34.

P.139 掲載の参考文献

1) Bazin E. Leions theriques et cliniques sur les affectations geeriques de la place. Vol 1. Paris : Delabrage ; 1862. p132.

2) Oono T, Arata J, Masuda T, et al. Coexistence of hydroa vacciniforme and malignant lymphoma. Arch Dermatol 1986 ; 122 : 1306-9.

3) Asada H, Okada N, Tei H, et al. Epstein-Barr virus-associated large granular lymphocyte leukemia with cutaneous infiltration. J Am Acad Dermatol 1994 ; 31 : 251-5.

4) Asada H, Okada N, Hashimoto K, et al. Establishment and characterization of the T-cell line, EBT-8 latently infected with Epstein-Barr virus from large granular lymphocyte leukemia. Leukemia 1994 ; 8 : 1415-23.

5) Cho KH, Kim CW, Lee DY, et al. An Epstein-Barr virus-associated lymphoproliferative lesion of the skin presenting as recurrent necrotic papulovesicles of the face. Br J Dermatol 1996 ; 134 : 791-6.

6) Iwatsuki K, Xu Z, Takata M, et al. The association of latent Epstein-Barr virus infection with hydroa vacciniforme. Br J Dermatol 1999 ; 140 : 715-21.

7) Hidano A, Kawakami M, Yago A. Hypersensitivity to mosquito bite and malignant histocytosis. Jpn J Exp Med 1982 ; 52 : 303-6.

8) Tokura Y, Tamura Y, Takigawa M, et al. Severe hypersensitivity to mosquito bites associated with natural killer cell lymphocytosis. Arch Dermatol 1990 ; 126 : 362-8.

9) Asada H, Miyagawa S, Sumikawa Y, et al. CD4+ T lymphocyte-induced Epstein-Barr virus reactivation in a patient with severe hypersensitivity to mosquito bites and Epstein-Barr virus infected NK cell lymphocytosis. Arch Dermatol 2003 ; 139 : 1601-7.

10) Asada H, Saito-Katsuragi M, Niizeki H, et al. Mosquito salivary gland extracts induce EBV-infected NK cell oncogenesis via CD4+ T cells in patients with hypersensitivity to mosquito bites. J Invest Dermatol 2005 ; 125 : 956-61.

11) Asada H. Hypersensitivity to mosquito bites : a unique pathogenic mechanism linking Epstein-Barr virus infection, allergy and oncogenesis. J Dermatol Sci 2007 ; 45 : 153-60.

12) Sato E, Ohga S, Kuroda H, et al. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol 2008 ; 83 : 721-7.

P.145 掲載の参考文献

1) Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med 2000 ; 342 : 1027-38.

2) Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994 ; 266 : 1865-9.

3) Ganem D. Kaposi's sarcoma-associated herpesvirus. Knipe DM, Howley PM, Griffin DE, et al, editors. Fields Virology. Vol 2. 5th ed. Philadelphia : Lippincott Williams & Wilkins ; 2007. pp2847-88.

4) Katano H, Iwasaki T, Baba N, et al. Identification of antigenic proteins encoded by human herpesvirus 8 and seroprevalence in the general population and among patients with and without Kaposi's sarcoma. J Virol 2000 ; 74 : 3478-85.

5) 安岡彰. 重篤な日和見感染症の早期発見と最適治療に関する研究. 平成18年度厚生労働省エイズ対策研究費報告書 2006 : 17.

6) Katano H, Sato Y, Kurata T, et al. High expression of HHV-8-encoded ORF73 protein in spindle-shaped cells of Kaposi's sarcoma. Am J Pathol 1999 ; 155 : 47-52.

7) Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome : a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989 ; 7 : 1201-7.

P.150 掲載の参考文献

1) Said J, Cesarman E. Primary effusion lymphoma. In : Swerdlow SH, et al, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon : International Agency for Research on Cancer (IARC) ; 2008. pp260-1.

2) Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma : a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996 ; 88 : 645-56.

3) Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995 ; 86 : 1276-80.

4) Suda T, Katano H, Delsol G, et al. HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. Pathol Int 2001 ; 51 : 671-9.

5) Katano H, Sato Y, Kurata T, et al. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 2000 ; 269 : 335-44.

6) Isaacson PG, Campo E, Harris NL. Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease. In : Swerdlow SH, et al, editors. WHO Classification of Tumours of Haematopoetic and Lymphoid Tissues. 4th ed. Lyon : International Agency for Research on Cancer (IARC) ; 2008. pp258-9.

III 急性発疹症とウイルス

P.154 掲載の参考文献

1) 日野治子. ウイルス感染症の鑑別法. 日皮会誌 2010 ; 120 : 993-1008.

1) 日野治子編著. こどもの発疹のみかた-急性発疹症へのアプローチ. 第3版, 東京 : 中外医学社 ; 2009.

2) 日野治子. 塩原哲夫編. 皮膚科診療プラクティス 19, 薬疹を極める. 東京 : 文光堂 ; 2006. pp240-50.

P.163 掲載の参考文献

1) Tatsuo H, Ono N, Tanaka K, et al. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000 ; 406 : 893-7.

2) Takeuchi K, Takeda M, Miyajima N, et al. Recombinant wild-type and Edmonston strain measles viruses bearing heterologous H proteins : role of H protein in cell fusion and host cell specificity. J Virol 2002 ; 76 : 4891-900.

3) 庵原俊昭. 麻疹ウイルス. 日本小児感染症学会編. 日常診療に役立つ小児感染症マニュアル 2003-2004. 東京 : 東京医学社 ; 2003. pp133-45.

4) 国立感染症研究所感染症情報センター. 感染症の話-麻疹. IDWR (Infectious Diseases Weekly Report Japan) 2001 ; 3 (28) : 14-7.

5) 日野治子. 麻疹. 玉置邦彦, ほか編. 最新皮膚科学大系第15巻, ウイルス性疾患性感染症. 東京 ; 中山書店 ; 2003. pp153-7,

6) 中島一敏. 麻疹. 小児科 2006 ; 47 : 429-36.

7) 加藤達夫. 定期予防接種実施に関する法改正. 小児科 2006 ; 47 : 421-7.

P.168 掲載の参考文献

1) 国立感染症研究所感染症情報センター. 風疹. 2001. http://idsc.nih.go.jp/idwr/kansen/k01_g2/k01_29/k01_29.html

2) 宮崎千明. 風疹. 小児内科 2010 ; 42 : 154-7.

3) 日野治子. 風疹. 渡辺晋一編. 皮膚感染症のすべて. 東京 : 南江堂 ; 2009. pp89-90.

4) 日野治子. 風疹. 日野治子編著. こどもの発疹のみかた. 第3版. 東京 : 中外医学社 ; 2009. pp31-9.

P.174 掲載の参考文献

1) 川上理子. エンテロウイルス感染症. 日野治子編著. こどもの発疹のみかた. 第3版. 東京 : 中外医学社 ; 2009. pp60-75.

2) 日野治子. エンテロウイルス感染症. 小児内科 2010 ; 42 : 176-9.

3) Lerner AM, Klein JO, Cherry JD, et al. New viral exanthems. N Engl J Med 1963 ; 269 : 678-85.

P.182 掲載の参考文献

1) De Gaspari G, Bardare M, Costantino D. AU antigen in Crosti-Gianotti acrodermatitis. Lancet 1970 ; 1 (7656) : 1116-7.

2) Ishimaru Y, Ishimaru H, Toda G, et al. An epidemic of infantile papular acrodermatitis (Gianotti's disease) in Japan associated with hepatitis-B surface antigen subtype ayw. Lancet 1976 ; 1 (7962) : 707-9.

3) Hofmann B, Schuppe HC, Adams O, et al. Gianotti-Crosti syndrome associated with Epstein-Barr virus infection. Pediatr Dermatol 1997 ; 14 : 273-7.

4) Gelmetti C. Gianotti-Crosti syndrome. In : Harper J, et al, editors. Textbook of Pediatric Dermatology. 2nd ed. Malden : Blackwell ; 2002. pp419-23.

5) Brandt O, Abeck D, Gianotti R, et al. Gianotti-Crosti syndrome. J Am Acad Dermatol 2006 ; 54 : 136-45.

6) Terasaki K, Koura S, Tachikura T, et al. Gianotti-Crosti syndrome associated with endogenous reactivation of Epstein-Barr virus. Dermatology 2003 ; 207 : 68-71.

7) Caputo R, Gelmetti C, Ermacora E, et al. Gianotti-Crosti syndrome : a retrospective analysis of 308 cases. J Am Acad Dermatol 1992 ; 26 : 207-10.

P.186 掲載の参考文献

1) 飯島茂子, 倉持美也子. 成人の伝染性紅斑18例の臨床的検討. 皮膚臨床 1998 ; 40 : 1427-32.

2) 浅野祐介, 塩原哲夫. ヒトパルボウイルスB19感染症. Visual Dermatol 2007 ; 6 : 1258-64.

3) Miller E, Fairley CK, Cohen BJ, et al. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol 1998 ; 105 : 174-8.

4) 清島真理子, 渋谷佳直, 加藤元一, ほか. 伝染性紅斑. Visual Dermatol 2010 ; 9 : 68-9.

P.192 掲載の参考文献

1) 熊野浩太郎. ヒトパルボウイルスB19感染症の様々な病態. 日臨免疫会誌 2008 ; 31 : 448-53.

2) 清島真理子. 成人のヒトパルボウイルスB19感染症. MB Derma 2006 ; 114 : 97-102.

3) Seishima M, Mizutani Y, Shibuya Y, et al. Chronic fatigue syndrome. Dermatology 2008 ; 216 : 341-6.

4) Pankuweit S, Ruppert V, Eckhardt H, et al. Pathophysiology and aetiological diagnosis of inflammatory myocardial diseases with a special focus on parvovirus B19. J Vet Med 2005 ; 52 : 344-7.

5) Seishima M, Shibuya Y, Suzuki S. Hyperthyroidism associated with human parvovirus B19 infection. Clin Exp Dermatol 2009 ; 34 : e439-40.

6) Nakazawa T, Tomosugi N, Sakamoto K, et al. Acute glomerulonephritis after human parvovirus B19 infection. Am J Kidney Dis 2000 ; 35 : E31.

7) Harms M, Feldmann R, Saurat JH. Papular-purpuric "gloves and socks" syndrome. J Am Acad Dermatol 1990 ; 23 : 850-4.

P.194 掲載の参考文献

1) 学校保健安全法 http://law.e-gov.go.jp/htmldata/S33/S33HO056.html : 学校保健安全法, 施行令, 施行規則.

2) 日野治子編著. こどもの発疹のみかた-急性発疹症へのアプローチ. 第3版. 東京 : 中外医学社 ; 2009.

3) 日野治子. 学校保健と学校感染症. 皮膚病診療 2009 ; 31 (増刊) : 89-101.

4) 日野治子. 学校感染症に関する日本臨床皮膚科医会の見解について. 日臨皮会誌 2004 ; 79 : 50.

P.206 掲載の参考文献

1) 井出麻衣子, 満山陽子, 平原和久, ほか. デング熱の2例. 臨皮 2008 ; 62 : 663-6.

2) 狩野葉子. 日常診療における薬疹とウイルス性発疹症の見分け方. 日臨皮会誌 2009 ; 26 : 251-4.

3) 塩原哲夫. ウイルス性発疹症か? 薬疹か? MB Derma 2010 ; 162 : 70-6.

4) 岡崎秀規, 藤山幹子, 村上信司, ほか. 薬剤性過敏症症候群 (DIHS) の特徴的な顔面の所見とHHV-6再活性化との時間的関係. 日皮会誌 2009 ; 119 : 2187-93.

5) Kano Y, Hirahara K, Mitsuyama Y, et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity : dependence on its timing and the type of drug eruption. Allergy 2007 ; 62 : 1439-44.

P.208 掲載の参考文献

1) 厚生労働省告示第442号. 麻しんに関する特定感染症予防指針. 2007. 12. 28.

2) 国立感染症研究所, 厚生労働省健康局結核感染症課. 麻疹 2009年. 病原微生物検出情報 2010 ; 31 : 33-4.

3) 国立感染症研究所, 厚生労働省健康局結核感染症課. 麻疹 2008年. 病原微生物検出情報 2009 ; 30 : 29-30.

4) IASR編集委員会. 麻疹ウイルスを直接証明する方法による検査診断の必要性. 病原微生物検出情報 2010 ; 31 : 265.

5) 田中敏博, 小栗泉, 川出博江. 伝染性紅斑の成人患者における血清中の麻疹ウイルスIgM抗体価の変動. 病原微生物検出情報 2010 ; 31 : 268-9.

6) 三浦裕一. 麻しんと診断された伝染性紅斑の家族例. 病原微生物検出情報 2010 ; 31 : 267-8.

7) 岩田眞美, 紺野美貴, 椎葉桂子, ほか. 麻しんか伝染性紅斑か診断に迷った症例. 病原微生物検出情報 2010 ; 31 : 265-6.

8) 佐藤弘, 多屋馨子, 高崎智彦, ほか. デング熱および突発性発疹と考えられる症例における麻疹IgM抗体陽性例. 病原微生物検出情報 2010 ; 31 : 269-71.

9) 国立感染症研究所感染症情報センター, 厚生労働省健康局結核感染症課. 感染症流行予測調査事業. 2010年11月時点. URL : http://idsc.nih.go.jp/yosoku/index.html

IV ヒト乳頭腫ウイルス

P.212 掲載の参考文献

1) de Villiers E-M, Fauquet C, Broker TR, et al. Classification of papilloma-viruses. Virology 2004 ; 324 : 17-27.

2) 白澤浩. 自然生態と増殖・分類. 清水文七編. パピローマウイルスによる腫瘍-基礎から臨床へのアプローチ. 東京 : 文光堂 ; 2000. pp21-45.

3) 富田善身. ゲノムの発現とウイルス粒子形成. 清水文七編. パピローマウイルスによる腫瘍-基礎から臨床へのアプローチ. 東京 : 文光堂 ; 2000. pp7-20.

4) Egawa K. Histochemical analysis of cutaneous HPV-associated lesions. In : Davy C, et al, editors. Human papillomaviruses : methods and protocols. Towata : Humana Press ; 2005. pp27-40.

5) 江川清文. いぼの基本病型 (典型像) と非典型像および臨床鑑別診断. 江川清文編著. カラーアトラス疣贅治療考-いぼ/コンジローマ/みずいぼ. 東京 : 医歯薬出版 ; 2005. pp12-30.

6) 田上八朗. 疣贅の自然消退現象. 江川清文編著. カラーアトラス疣贅治療考-いぼ/コンジローマ/みずいぼ. 東京 : 医歯薬出版 ; 2005. pp53-5.

7) 江川清文. Bowen病, bowenoid papulosis, verrucous carcinomaとHPV. 皮膚臨床 1999 ; 41 : 1085-91.

8) Boxman ILA, Berkhout RJM, Mulder LHC, et al. Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 1997 ; 108 : 712-5.

9) 川瀬正昭. epidermodysplasia verruciformis (疣贅状表皮発育異常症). Visual Dermatol 2010 ; 9 : 252-5.

10) de Villiers E-M. Prevalence of HPV 7 papillomas in the oral mucosa and facial skin of patients with human immunodeficiency virus. Arch Dermatol 1989 ; 125 : 1590.

11) Egawa K. New types of human papillomaviruses and intracytoplasmic inclusion bodies : a classification of inclusion warts according to clinical features and associated HPV types. Br J Dermatol 1994 ; 130 : 158-66.

12) zur Hausen H. Papillomavirus infections : a major cause of human cancers. Biochim Biophys Acta 1996 ; 1228 : F55-78.

P.218 掲載の参考文献

1) 江川清文編著. カラーアトラス疣贅治療考-いぼ/コンジローマ/みずいぼ. 東京 : 医歯薬出版 ; 2005.

1) 横山眞爲子, 奥村之啓, 江川清文. 地方都市皮膚科診療所におけるウイルス性疣贅と伝染性軟属腫の疫学的特徴の比較検討. 日皮会誌 2010 ; 120 : 871-80.

2) 江川清文. 尋常性疣贅. 玉置邦彦, ほか編. 最新皮膚科学大系 15, ウイルス性疾患性感染症. 東京 : 中山書店 ; 2003. pp70-7.

3) 江川清文. 疣贅治療考. 皮膚臨床 2004 ; 46 : 1799-807.

4) 三宅大我, 永田貴久, 江川清文. ドーナツ疣贅-液体窒素凍結療法の副作用. Visual Dermatol 2010 ; 9 : 232-3.

5) Sterling JC, Handfield-Jones S, Hudson PM. Guidelines for the management of cutaneous warts. Br J Dermatol 2001 ; 144 : 4-11,

6) 江川清文. 尋常生疣贅-よい治療法はないですか? 橋本公二, ほか編. 皮膚科診療プラクティス 10, 治療にてこずる皮膚疾患. 東京 : 文光堂 ; 2000. pp82-7.

7) 江川清文. ウイルス性疣贅. 皮膚臨床 2003 ; 45 : 1467-73.

8) 江川清文. 液体窒素以外の疣贅治療法. 日皮会誌 2004 ; 114 : 2249-55.

9) 大石空. ミルメシア-典型像の提示といぼ剥ぎ法による治療. Visual Dermatol 2010 ; 9 : 234-5.

10) Egawa K, Ono T. Topical vitamin D3 derivatives for recalcitrant warts in three immunocompromised patients. Br J Dermatol 2004 ; 150 : 374-6.

11) 稲葉浩子, 鈴木民夫, 富田靖. 手掌の多発性難治性疣贅に対し活性化ビタミンD3軟膏とサリチル酸絆創膏併用療法が奏効した1例. 臨床皮膚 2005 ; 59 : 1339-41.

P.225 掲載の参考文献

1) 江川清文. 扁平疣贅. 玉置邦彦, ほか編. 最新皮膚科学大系 15, ウイルス性疾患性感染症. 東京 : 中山書店 ; 2003. pp78-80.

2) 田上八朗. 疣贅の自然消退現象. 江川清文編著. カラーアトラス疣贅治療考-いぼ/コンジローマ/みずいぼ. 東京 : 医歯薬出版 ; 2005. pp53-5.

3) 服部瑛. 一般外来診療における疣贅の統計-第2報. 皮膚病診療 1997 ; 19 : 563-6.

4) 横山眞爲子, 奥村之啓, 江川清文. 地方都市皮膚科診療所におけるウイルス性疣贅と伝染性軟属腫の疫学的特徴の比較検討. 日皮会誌 2010 ; 120 : 871-80.

5) 上田由紀子. 青年性扁平疣贅の治癒率. 日皮会誌 1985 ; 95 : 985-93.

6) Pfister H, Gross G, Hagedorn M. Characterization of human papillomavirus in warts of a renal allograft patient. J Invest Dermatol 1979 ; 73 : 349-53.

7) 江川清文. 疣贅治療総論. 江川清文編著. カラーアトラス疣贅治療考-いぼ/コンジローマ/みずいぼ. 東京 : 医歯薬出版 ; 2005. pp50-2.

8) 谷口彰治. ヨクイニンエキス内服. 江川清文編著. カラーアトラス疣贅治療考-いぼ/コンジローマ/みずいぼ. 東京 : 医歯薬出版 ; 2005. pp133-4.

9) 江川清文. シメチジン内服. 江川清文編著. カラーアトラス疣贅治療考-いぼ/コンジローマ/みずいぼ. 東京 : 医歯薬出版 ; 2005. pp135-7.

10) Egawa K, Ono T. Topical vitamin D3 derivatives for recalcitrant warts in three immunocompromised patients. Br J Dermatol 2004 ; 150 : 374-6.

11) 江川清文. 扁平疣贅成人下腿の難治例-活性型ビタミンD3外用. 江川清文編著. カラーアトラス疣贅治療考-いぼ/コンジローマ/みずいぼ. 東京 : 医歯薬出版 ; 2005. pp182.

12) 相川美和, 落合豊子, 阿部郁子. アルファカルシドール内服中に発症しタカルシトール外用療法が奏効した青年性扁平疣贅. 皮膚科の臨床 2007 ; 49 : 809-12.

13) 角田寿之. ビダラビン外用. 江川清文編著. カラーアトラス疣贅治療考-いぼ/コンジローマ/みずいぼ. 東京 : 医歯薬出版 ; 2005. pp110-1.

14) 江川清文. 接触免疫療法. 江川清文編著. カラーアトラス疣贅治療考-いぼ/コンジローマ/みずいぼ. 東京 : 医歯薬出版 ; 2005. pp120-2.

15) 大石空. 接触免疫療法 (DNCB, DPCP, SADBE). 江川清文編著. カラーアトラス疣贅治療考-いぼ/コンジローマ/みずいぼ. 東京 : 医歯薬出版 ; 2005. pp117-9.

16) 幸田公人, 川瀬正昭, 石地尚興, ほか. 扁平疣贅-典型像の提示と接触免疫療法 (SADBE) による治療. Visual Dermatology 2010 ; 9 : 226-7.

17) 本田まりこ. フルオロウラシル (5-FU) 外用. 江川清文編著. カラーアトラス疣贅治療考-いぼ/コンジローマ/みずいぼ. 東京 : 医歯薬出版 ; 2005. pp104-5.

18) Lin MY, Xiang LH. Topical 5-aminolevulinic acid photo-dynamic therapy for recalcitrant facial flat wart in Chinese subjects. J Dermatol 2008 ; 35 : 658-61.

19) 新山史朗, 勝岡憲生. イミキモド5%クリームが奏効した顔面の扁平疣贅-尋常性疣贅効果例を加えて. 皮膚病診療 2010 ; 32 : 179-82.

P.230 掲載の参考文献

1) Lyell A, Miles JAR. The myrmecia : a study of inclusion bodies in warts. Br Med J 1951 ; 1 : 912-5.

2) Laurent R, Kienzler JL, Croissant O, et al. Two anatomical types of warts with plantar localization : Specific cytopathic effects of papillomavirus type 1 (HPV-1) and type 2 (HPV-2). Arch Dermatol Res 1982 ; 274 : 101-11.

3) 江川清文. いぼの基本病型 (典型像) と非典型像および臨床鑑別診断. 江川清文編著. 疣贅治療考-いぼ/コンジローマ/みずいぼ. 東京 : 医歯薬出版. 2005. pp12-30.

4) 本田由美. 封入体疣贅. Visual Dermatology 2010 ; 9 : 248-50.

5) Egawa K. Genus gamma-and mu-papillomaviruses : clinical and histopathological aspects suggestive of their important roles in virology and human pathology. Current Topics in Virology 2007 ; 6 : 53-66.

6) Egawa K, Inaba Y, Yoshimura K, et al. Varied clinical morphology of HPV-1-induced warts, depending on anatomical factors. Br J Dermatol 1993 ; 128 : 271-6.

7) 久保秀通, 江川長靖, 清野透, ほか. 指状疣贅かミルメシアか? -指状疣贅様臨床像を呈した特異なミルメシア. Visual Dermatology 2010 ; 9 : 228-9.

8) Egawa K. New types of human papillomaviruses and intracytoplasmic inclusion bodies : A classification of inclusion warts according to clinical features, histology and associated HPV types. Br J Dermatol 1994 ; 130 : 158-66.

9) Honda A, Iwasaki T, Sata T, et al. Human papillomavirus 60-associated plantar wart : ridged wart. Arch Dermatol 1994 ; 130 : 1413-7.

10) 江川清文, ほか. ミルメシアにおけるレクチン結合様式-ABC法による組織化学的検討. 日皮会誌1987 ; 97 : 737-43.

11) 江川清文. ミルメシアとは異なる封入体疣贅の存在について. 日皮会誌 1988 ; 98 : 1105-12.

12) Egawa K, Honda Y, Inaba Y, et al. Pigmented viral warts : a clinical and histopathological study including human papillomavirus typing. Br J Dermatol 1998 ; 138 : 381-9.

13) Kashima M, Adachi M, Honda M, et al. A case of peculiar plantar warts : human papillomavirus type 60 infection. Arch Dermatol 1994 ; 130 : 1418-21.

14) Egawa K, Inaba Y, Ono T, et al. 'Cystic papilloma' in humans? Demonstration of human papillomavirus in plantar epidermoid cyst. Arch Dermatol 1990 ; 126 : 1599-603.

15) Matsukura T, Iwasaki T, Kawashima M. Molecular cloning of a novel human papillomavirus (HPP 60) from a plantar cyst with characteristic changes. Virology 1992 ; 190 : 561-4.

16) Egawa K, Egawa N, Honda Y. Human papillomavirus-associated plantar epidermoid cyst related to epidermoid metaplasia of the eccrine duct epithelium : a combined histological, immunohistochemical, DNA-DNA in situ hybridization and three-dimensional reconstruction analysis. Br J Dermatol 2005 ; 152 : 961-7.

17) Egawa K, Kitasato H, Honda Y, et al. Human papillomavirus 57 identified in an plantar epidermoid cyst. Br J Dermatol 1998 ; 138 : 510-4.

18) Egawa K, Kimmel R, de Villiers EM. A novel type of human papillomavirus (HPV95) : comparison with infections of closely related human papillomavirus types. Br J Dermatol 2005 ; 153 : 688-9.

P.236 掲載の参考文献

1) de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004 ; 324 : 17-27.

2) 中川秀己. 尖圭コンジローマ. 日性感染症会誌 2009 ; 20 : 41-4.

3) Mo LZ, Monnier-Benoit S, Kantelip B, et al. Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology : use of INNO-LiPA Genotyping assay to screen the discordant results. J Clin Virol 2008 ; 41 : 104-10.

4) Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002 ; 3 : 196-200.

5) 広瀬崇興, 吉川裕之, 本田まりこ. 尖圭コンジローマ-その他の性器ヒト乳頭腫ウイルス感染症を含む. 日性感染症会誌 2008 ; 19 : 67-70.

P.240 掲載の参考文献

1) Wade TR, Kopf AW, Ackerman AB. Bowenoid papulosis of the genitalia. Arch Dermatol 1979 ; 115 : 306-8.

2) De Villez RL, Stevens CS. Bowenoid papules of the genitalia : a case progressing to Bowen's disease. J Am Acad Dermatol 1980 ; 3 : 149-52.

3) 石地尚興, 峰咲幸哲, 福代三根, ほか. 外陰部ヒト乳頭腫ウイルス感染症の臨床・組織学的特徴-第一報・悪性型について. 日性感染症会誌 1993 ; 4 : 126-32.

4) Ibe M, Kawase M, Ishiji T, et al. A cardiac allograft recipient with Bowen's disease on a finger and concurrent perianal bowenoid papulosis. J Dermatol (Tokyo) 2003 ; 30 : 389-94.

5) Ikenberg H, Gissmann L, Gross G, et al. Human papillomavirus type-16-related DNA in genital Bowen's disease and in bowenoid papulosis. Int J Cancer 1983 ; 32 : 563-5.

6) Petrow W, Gerdsen R, Uerlich M, et al. Successful topical immunotherapy of bowenoid papulosis with imiquimod. Br J Dermatol 2001 ; 145 : 1022-3.

P.244 掲載の参考文献

1) Sapp M, Bienkowska-Haba M. Viral entry mechanisms : human papillomavirus and a long journey from extracellular matrix to the nucleus. FEBS J 2009 ; 276 (24) : 7206-16.

2) Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intraepithelial lesions in young women. Lancet 2004 ; 364 : 1678-83.

3) Kiyono T, Foster SA, Koop JI, et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998 ; 396 : 84-8.

4) Kawauchi K, Ihjima K, Yamada O. IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3'-kinase/Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells. J Immunol 2005 ; 174 : 5261-9.

5) Veldman T, Liu X, Yuan H, et al. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc Natl Acad Sci U S A 2003 ; 100 : 8211-6.

6) Munger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirusinduced oncogenesis. J Virol 2004 ; 78 : 11451-60.

7) Mitsuishi T, Iwabu Y, Tokunaga K, et al. Combined analysis of cell growth and apoptosis-regulating proteins in HPVs associated anogenital tumors. BMC Cancer 2010 ; 10 : 118.

8) Kyo S, Nakamura M, Kiyono T, et al. Successful immortalization of endometrial glandular cells with normal structural and functional characteristics. Am J Pathol 2003 ; 163 : 2259-69.

9) Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by highrisk human papillomaviruses : novel functions of E6 and E7 oncoproteins. Rev Med Virol 2009 ; 19 (2) : 97-113.

10) Darnell GA, Schroder WA, Antalis TM, et al. Human papillomavirus E7 requires the protease calpain to degrade the retinoblastoma protein. J Biol Chem 2007 ; 282 (52) : 37492-500.

11) Klaes R, Woerner SM, Ridder R, et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 1999 ; 59 (24) : 6132-6.

12) Pett M, Coleman N. Integration of high-risk human papillomavirus : a key event in cervical carcinogenesis? J Pathol 2007 ; 212 (4) : 356-67.

13) Paavonen J, Naud P, Salmeron J, et al. HPV PATRICIA Study Group, Greenacre M. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA) : final analysis of a double-blind, randomised study in young women. Lancet 2009 ; 374 (9686) : 301-14.

14) Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV ; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009 ; 199 (7) : 936-44.

15) Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004 ; 111 (2) : 278-85.

P.252 掲載の参考文献

1) Lewandowsky F, Lurz W. Ein Fall einer bisher nicht beschriebenen Hauterkrankung (Epidermodysplasia verruciformis). (in German) Archiv fur Dermatologie und Syphilis. 1922 ; 141 : 193-203.

2) Ramoz N, Rueda LA, Bouadjar B, et al. A susceptibility locus for epidermodys-plasia verruciformis, an abnormal predisposition to infection with the oncogenic human papillomavirus type 5, maps to chromosome 17qter in a region containing a psoriasis locus. J Invest Dermatol 1999 ; 112 (3) : 259-63.

3) Ramoz N, Rueda LA, Bouadjar B, et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002 ; 32 (4) : 579-81.

4) Kurima K, Yang Y, Sorber K, et al. Characterization of the transmembrane channel-like (TMC) gene family : functional clues from hearing loss and epidermodysplasia verruciformis. Genomics 2003 ; 82 (3) : 300-8.

5) Keresztes G, Mutai H, Heller S. TMC and EVER genes belong to a larger novel family, the TMC gene family encoding transmembrane proteins. BMC Genomics 2003 ; 4 (1) : 24.

6) Orth G. Genetics of epidermodysplasia verruciformis : insights into host defense against papillomaviruses. Semin Immunol 2006 ; 18 : 362-74.

7) Tate G, Suzuki T, Kishimoto K, et al. Novel mutations of EVER1/TMC6 gene in a Japanese patient with epidermodysplasia verruciformis. J Hum Genet 2004 ; 49 (4) : 223-5.

8) Sun XK, Chen JF, Xu AE. A homozygous nonsense mutation in the EVER2 gene leads to epidermodysplasia verruciformis. Clin Exp Dermatol 2005 ; 30 (5) : 573-4.

9) Zuo YG, Ma D, Zhang Y, et al. Identification of a novel mutation and a genetic polymorphism of EVER1 gene in two families with epidermodysplasia verruciformis. J Dermatol Sci 2006 ; 44 (3) : 153-9.

10) Gober MD, Rady PL, He Q, et al. Novel homozygous frameshift mutation of EVER1 gene in an epidermodysplasia verruciformis patient. J Invest Dermatol 2007 ; 127 (4) : 817-20.

11) Aochi S, Nakanishi G, Suzuki N, et al. A novel homozygous mutation of the EVER1/TMC6 gene in a Japanese patient with epidermodysplasia verruciformis. Br J Dermatol 2007 ; 157 (6) : 1265-6.

12) Berthelot C, Dickerson MC, Rady P, et al. Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. J Am Acad Dermatol 2007 ; 56 (5) : 882-6.

13) Patel AS, Karagas MR, Pawlita M, et al. Cutaneous human papillomavirus infection, the EVER2 gene and incidence of squamous cell carcinoma : a casecontrol study. Int J Cancer 2008 ; 122 (10) : 2377-9.

14) Hohenstein E, Rady PL, Hergersberg M, et al. Epidermodysplasia verruciformis in a HIV-positive patient homozygous for the c917A-->T polymorphism in the TMC8/EVER2 gene. Dermatology 2009 ; 218 (2) : 114-8.

15) Akgul B, Kose O, Safali M, et al. A distinct variant of Epidermodysplasia verruciformis in a Turkish family lacking EVER1 and EVER2 mutations. J Dermatol Sci 2007 ; 46 (3) : 214-6.

16) McDermott DF, Gammon B, Snijders PJ, et al. Autosomal dominant epidermodysplasia verruciformis lacking a known EVER1 or EVER2 mutation. Pediatr Dermatol 2009 ; 26 (3) : 306-10.

17) Azzimonti B, Mondini M, De Andrea M, et al. CD8+ T-cell lymphocytopenia and lack of EVER mutations in a patient with clinically and virologically typical epidermodysplasia verruciformis. Arch Dermatol 2005 ; 141 : 1323-5.

18) Ramoz N, Taieb A, Rueda LA, et al. Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q25. J Invest Dermatol 2000 ; 114 (6) : 1148-53.

19) Lazarczyk M, Favre M. Role of Zn2+ ions in host-virus interactions. J Virol 2008 ; 82 (23) : 11486-94.

20) Lazarczyk M, Pons C, Mendoza JA, et al. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J Exp Med 2008 ; 205 (1) : 35-42.

21) Lazarczyk M, Cassonnet P , Pons C, et al. The EVER proteins as a natural barrier against papillomaviruses : a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009 ; 73 (2) : 348-70.

22) de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004 ; 324 (1) : 17-27.

23) Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010 ; 401 (1) : 70-9.

24) Kawase M, Orth G, Jablonska S, et al. Variability and phylogeny of the L1 capsid protein gene of human papillomavirus type 5 : contribution of clusters of nonsynonymous mutations and of a 30-nucleotide duplication. Virology 1996 ; 221 : 189-98.

25) Kawase M, Honda M, Niimura M. Detection of human papillomavirus type 60 in plantar cysts and verruca plantaris by the in situ hybridization method using digoxigenin labeled probes. J Dermatol 1994 ; 21 (10) : 709-15.

26) Berkhout RJ, Tieben LM, Smits HL, et al. Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J Clin Microbiol 1995 ; 33 (3) : 690-5.

27) Favre M, Orth G, Majewski S, et al. Psoriasis : A possible reservoir for human papillomavirus type 5, the virus associated with skin carcinomas of epidermodysplasia verruciformis. J Invest Dermatol 1998 ; 110 (4) : 311-7.

28) Boxman IL, Mulder LH, Russell A, et al. Human papillomavirus type 5 is commonly present in immunosuppressed and immunocompetent individuals. Br J Dermatol 1999 ; 141 (2) : 246-9.

29) Boxman IL, Russell-A, Mulder LH, et al. Association between epidermodysplasia verruciformis-associated human papillomavirus DNA in plucked eyebrow hair and solar keratoses. J Invest Dermatol 2001 ; 117 (5) : 1108-12.

30) Berger TG, Sawchuk WS, Leonardi C, et al. Epidermodysplasia verruciformisassociated papillomavirus infection complicating human immunodeficiency virus disease. Br J Dermatol 1991 ; 124 : 79-83.

31) Rogers HD, Macgregor JL, Nord KM, et al. Acquired epidermodysplasia verruciformis. J Am Acad Dermatol 2009 ; 60 (2) : 315-20.

32) Gul U, Kilic A, Gonul M, et al. Clinical aspects of epidermodysplasia verruciformis and review of the literature. Int J Dermatol 2007 ; 46 : 1069-72.

33) Gewirtzman A, Bartlett B, Tyring S. Epidermodysplasia verruciformis and human papilloma virus. Curr Opin Infect Dis 2008 ; 21 : 141-6.

34) Pfister H, Fuchs PG, Majewski S, et al. High prevalence of epidermodysplasia verruciformis-associated human papillomavirus DNA in actinic keratoses of the immunocompetent population. Arch Dermatol Res 2003 ; 295 : 273-9.

35) Weissenborn SJ, Nindl I, Purdie K, et al. Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol 2005 ; 125 : 93-7.

36) Weissenborn SJ, Hopfl R, Weber F, et al. High prevalence of a variety of epidermodysplasia verruciformis-associated human papillomaviruses in psoriatic skin of patients treated or not treated with PUVA. J Invest Dermatol 1999 ; 113 : 122-6.

37) Li YH, Chen G, Dong XP, et al. Detection of epidermodysplasia verruciformisassociated human papillomavirus DNA in nongenital seborrhoeic keratosis. Br J Dermatol 2004 ; 151 : 1060-5.

38) Carlson JA, Cribier B, Nuovo G, et al. Epidermodysplasia verruciformis-associated and genital-mucosal high-risk human papillomavirus DNA are prevalent in nevus sebaceus of Jadassohn. J Am Acad Dermatol 2008 ; 59 : 279-94.

39) Ramagosa R, de Villiers EM, Fitzpatrick JE, et al. Human papillomavirus infection and ultraviolet light exposure as epidermoid inclusion cyst risk factors in a patient with epidermodysplasia verruciformis? J Am Acad Dermatol 2008 ; 58 : S68. e61-6.

40) Lin MT, Rohwedder A, Mysliborski J, et al'. HPV vulvitis'revisited : frequent and persistent detection of novel epidermodysplasia verruciformis-associated HPV genotypes. J Cutan Pathol 2008 ; 35 : 259-72.

41) Rohwedder A, Slominski A, Wolff M, et al. Epidermodysplasia verruciformis and cutaneous human papillomavirus DNA, but not genital human papillomavirus DNAs, are frequently detected in vulvar and vaginal melanoma. Am J Dermatopathol 2007 ; 29 : 13-7.

42) Antonsson A, Erfurt C, Hazard K, et al. Prevalence and type spectrum of human papillomaviruses in healthy skin samples collected in three continents. J Gen Virol 2003 ; 84 : 1881-6.

43) 川瀬正昭. バキュロウイルス-昆虫細胞発現系で産生されたヒト乳頭腫ウイルス5型のL1カプシド蛋白が形成したウイルス様粒子. 慈恵医大誌 1996 ; 111 : 75-83.

44) Stark S, Petridis AK, Ghim S, et al. Prevalence of antibodies against virus-like particles of Epidermodysplasia verruciformis-associated HPV8 in patients at risk of skin cancer. J Invest Dermatol 1998 ; 111, 696-701.

V レトロウイルス

P.260 掲載の参考文献

1) Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983 ; 220 : 868-71.

2) Schwartz JJ, Myskowski PL. Molluscum contagiosum in patients with human immunodeficiency virus infection. A review of twenty-seven patients. J Am Acad Dermatol 1992 ; 27 : 583-8.

3) 赤城久美子, 林さなえ, 宮崎貴子. HIV感染者の皮膚病変-224例の臨床的検討. 日皮会誌 2000 ; 110 : 9-17.

4) Greenspan JS, Greenspan D, Lennette ET, et al. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N Engl J Med 1985 ; 313 : 1564-71.

5) Katz MH, Greenspan D, Westenhouse J, et al. Progression to AIDS in HIVinfected homosexual and bisexual men with hairy leukoplakia and oral candidiasis. AIDS 1992 ; 6 : 95-100.

6) Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994 ; 266 : 1865-9.

7) Mathes BM, Douglass MC. Seborrheic dermatitis in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol 1985 ; 13 : 947-51.

8) Liautaud B, Pape JW, DeHovitz JA, et al. Pruritic skin lesions. A common initial presentation of acquired immunodeficiency syndrome. Arch Dermatol 1989 ; 125 : 629-32.

9) Fearfield LA, Rowe A, Francis N, et al. Itchy folliculitis and human immunodeficiency virus infection : clinicopathological and immunological features, pathogenesis and treatment. Br J Dermatol 1999 ; 141 : 3-11.

10) Coopman SA, Johnson RA, Platt R, et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993 ; 328 : 1670-4.

11) Saiag P, Caumes E, Chosidow O, et al. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992 ; 26 : 567-74.

P.267 掲載の参考文献

1) 川村龍吉, 島田眞路. ランゲルハンス細胞とHIV. 日皮アレルギー会誌 2006 ; 14 : 1-6.

2) Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000 ; 74 : 6087-95.

3) Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV patients with primary infection. Science 1993 ; 261 : 1179-81.

4) Samson M, Libert F, Doranz BJ, et al. Resistance to HIV infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996 ; 382 : 722-5.

5) Kawamura T, Cohen SS, Borris DL, et al. Candidate microbicides block HIV infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med 2000 ; 192 : 1491-500.

6) Kawamura T, Gulden FO, Sugaya M, et al. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci U S A 2003 ; 100 : 8401-6.

7) 川村龍吉. HIV感染症におけるLangerhans細胞の役割. 炎症と免疫 2009 ; 17 : 308-12.

8) Geijtenbeek TB, Kwon DS, Torensma R, et al. DC-SIGN, a dendritic cellspecific HIV-binding protein that enhances trans-infection of T cells. Cell 2000 ; 100 : 587-97.

9) McDonald D, Wu L, Bohks SM, et al. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003 ; 300 : 1295-7.

10) Witte L, Nabatov A, Pion M, et al. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat Med 2007 ; 13 : 367-71.

P.269 掲載の参考文献

1) Hino S, Katamine S, Miyata H, et al. Primary prevention of HTLV-I in Japan. J Acquir Immune Defic Syndr Hum Retrovirol 1996 ; 13 (Suppl 1) : S199-203.

2) Takezaki T, Tajima K, Ito M, et al. Short-term breast-feeding may reduce the risk of vertical transmission of HTLV-I. The Tsushima ATL Study Group. Leukemia 1997 ; 11 (Suppl 3) : 60-2.

3) Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991 ; 79 : 428-37.

4) Johno M, Ohishi M, Kojo Y, et al. Cutaneous manifestation of adult T-cell leukemia/lymphoma. In : Takatsuki K, et al, editors. Advances in Adult T-Cell Leukemia and HTLV-1 Research. Tokyo : Japan Scientific Societies Press ; 1992. pp33-41.

5) Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma : Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007 ; 25 : 5458-64.

6) Abe Y, Yashiki S, Choi I, et al. Eradication of virus-infected T-cells in a case of adult T-cell leukemia/lymphoma by nonmyeloablative peripheral blood stem cell transplantation with conditioning consisting of low-dose total body irradiation and pentostatin. Int J Hematol 2002 ; 76 : 91-3.

7) Yonekura K, Utsunomiya A, Takatsuka Y, et al. Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008 ; 41 : 1029-35.

VI その他のウイルス

P.276 掲載の参考文献

1) Watanabe T, Morikawa S, Suzuki K, et al. Two major antigenic polypeptides of molluscum contagiosum virus. J Infect Dis 1998 ; 177 : 284-92.

2) 新関寛二. 子供の外科的処置を考える-痛くないみずいぼ取り40%硝酸銀ペースト法について. 日小皮会誌 2000 ; 19 : 141.

3) 神崎保, 溝口志真子. 健常人, 悪性黒色腫および成人T細胞白血病患者に対するヨクイニンの効果-NK活性とIFN-γの変動. 西日皮膚 2004 ; 66 : 490-3.

4) 高橋邦明, 石井正光, 依藤時子, ほか. ヨクイニンエキス製剤による伝染性軟属腫の治療経験. 皮膚 1987 ; 29 : 339-44.

5) ヨクイニンエキス散研究班. 伝染性軟属腫に対する「ヨクイニンエキス散」の臨床効果-placeboを対照とした多施設二重盲検法による比較試験. 皮膚 1987 ; 29 : 762.

6) 江川清文. 小児に多い感染症疣贅, 軟属腫. MB Derma 2004 ; 93 : 85-93.

7) 日野治子. 学校保健と学校感染症. 皮膚病診療 2009 ; 31 (増刊) : 89-101.

P.282 掲載の参考文献

1) 早川和人. 肝・膵疾患と皮膚病変肝炎ウイルスによる皮膚症状. 玉置邦彦, ほか編. 最新皮膚科学大系第18巻. 全身疾患と皮膚病変. 東京 : 中山書店 ; 2002. pp84-6.

2) McElgunn PSJ. Dermatologic manifestations of hepatitis B virus infection. J Am Acad Dermatol 1983 ; 8 : 539-48.

3) 日野治子. Gianotti病 Gianotti症候群. 玉置邦彦, ほか編. 最新皮膚科学大系第15巻. ウイルス性疾患性感染症. 東京 : 中山書店 ; 2002. pp163-7.

4) Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection : The case against autoimmune intervention in pathogenesis. J Autoimmun 2001 ; 16 : 269-74.

5) Guillevin L, Mahr A, Callard P, et al, for the French Vasculitis Study Group. Hepatitis B virus-associated polyarteritis nodosa. Clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine 2005 ; 84 : 313-22.

6) Pawlotsky JM, Dhumeaux D, Bagot M. Hepatitis C virus in dermatology. A review. Arch Dermatol 1995 ; 131 : 1185-93.

7) 野中薫雄, 上里博. 代謝・酵素障害による色素沈着症晩発性皮膚ポルフィリン症. 玉置邦彦, ほか編. 最新皮膚科学大系第8巻. 色素異常症. 東京 : 中山書店 ; 2002. pp210-3.

P.288 掲載の参考文献

1) Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008 ; 319 : 1096-100.

2) DeCaprio JA. Does detection of Merkel cell polyomavirus in Merkel cell carcinoma provide prognostic information? J Natl Cancer Inst 2009 ; 101 : 905-7.

3) Kantola K, Sadeghi M, Lahtinen A, et al. Merkel cell polyomavirus DNA in tumorfree tonsilar tissues and upper respiratory tract samples: implications for respiratory transmission and latency. J Clin Virol 2009 ; 45 : 292-5.

4) Babakir-Mina M, Ciccozzi M, Lo Presti A, et al. Identification of Merkel cell polyomavirus in the lower respiratory tract of Italian patients. J Med Virol 2010 ; 82 : 505-9.

5) Mertz KD, Junt T, Schmid M, et al. Inflammatory monocytes are a reservoir for Merkel cell polyomavirus. J Invest Dermatol 2010 ; 130 : 1146-51. Epub 2009

6) Shuda M, Arora R, Kwun HJ, et al. Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int J Cancer 2009 ; 125 : 1243-9.

7) Wieland U, Mauch C, Kreuter A, et al. Merkel cell polyomavirus DNA in persons without Merkel cell carcinoma. Emerg Infect Dis 2009 ; 15 : 1496-8.

8) Foulongne V, Dereure O, Kluger N, et al. Merkel cell polyomavirus DNA detection in lesional and nonlesional skin from patients with Merkel cell carcinoma of the skin diseases. Br J Dermatol 2010 ; 162 : 59-63.

9) Tolstov YL, Pastrana DV, Feng H, et al. Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer 2009 ; 125 : 1250-6.

10) Carter JJ, Paulson KG, Wipf GC, et al. Association of Merkel cell polyomavirusspecific antibodies with Merkel cell carcinoma. J Natl Cancer Inst 2009 ; 101 : 1510-22.

11) Pastrana DV, Tolstov YL, Becker JC, et al. Quantification of human seroresponsiveness to Merkel cell polyomavirus. PLos Pathog 2009 Doi : 10.1371/journal.ppat.1000578.s003.

12) Nakajima H, Takaishi M, Yamamoto M. Screening of the specific polyoma virus as diagnostic and prognostic tools for Merkel cell carcinoma. J Dermatol Sci 2009 ; 56 : 211-3.

13) Bhatia K, Goedert JJ, Modali R, et al. Immunological detection of viral large T antogen identifies a subset of Merkel cell carcinoma tumors with higher viral abundance and better clinical outcome. Int J Cancer 2009 DOI : 10.1002/ijc.25136.

14) Sihto H, Kukko H, Koljonen V, et al. Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst 2009 ; 101 : 938-45.

15) Kassem A, Technau K, Kurz AK, et al. Merkel cell polyomavirus sequence are frequently detected in nonmelanoma skin cancer if immunosuppressed patients. Int J Cancer 2009 ; 125 : 356-61.

16) Dworkin AM, Tseng SY, Allain DC, et al. Merkel cell polyomavirus in cutaneous squamous cell carcinoma of immunocompetent individuals. J Invest Dermatol 2009 ; 129 : 2868-74.

17) Katano H, Ito H, Suzuki Y, et al. Detection of merkel cell polyomavirus in Merkel cell carcinoma and kaposi's sarcoma. J Med Virol 2009 ; 81 : 1951-8.

書評

書評を投稿する

最近チェックした商品履歴

Loading...